Valuation: Senzime AB

Capitalization 913M 100M 84.95M 77.86M 73.94M 137M 9.31B 140M 359M 4.49B 375M 368M 15.87B P/E ratio 2025
-5.81x
P/E ratio 2026 * -
Enterprise value 913M 100M 84.95M 77.86M 73.94M 137M 9.31B 140M 359M 4.49B 375M 368M 15.87B EV / Sales 2025
8.16x
EV / Sales 2026 * -
Free-Float
53.5%
Yield 2025 *
-
Yield 2026 * -
1 day+5.64%
1 week+27.13%
Current month+38.50%
1 month+33.87%
3 months+14.60%
6 months-0.85%
Current year+7.59%
1 week 4.6
Extreme 4.6
6
1 month 3.96
Extreme 3.96
6
Current year 3.85
Extreme 3.85
6
1 year 3.85
Extreme 3.85
7.38
3 years 2.6
Extreme 2.605
9.6
5 years 2.6
Extreme 2.605
26
10 years 2.6
Extreme 2.605
28.5
Manager TitleAgeSince
Chief Executive Officer 53 2023-05-02
Director of Finance/CFO 56 2021-12-31
Chief Tech/Sci/R&D Officer 50 2022-12-31
Director TitleAgeSince
Chairman 78 2023-10-31
Director/Board Member 73 2022-12-31
Chairman 53 2023-05-02
Change 5d. change 1-year change 3-years change Capi.($)
+5.64%+27.13%+51.70%+10.88% 94.72M
-0.84%-4.66%-26.71%-13.00% 169B
-1.38%-3.41%+2.91%+1.81% 111B
-1.39%+1.22%+12.65%+94.63% 63.72B
-1.10%-0.22%+87.98%+111.20% 61.53B
+0.06%+2.07%-20.17%-39.43% 45.14B
+1.30%+2.20% - - 38.67B
+1.00%+2.38%-5.76%-47.12% 24.69B
+0.27%+0.69%+1.88%+22.09% 22.14B
-1.06%+7.36%-0.24%-26.55% 21.67B
Average +0.38%+3.66%+11.58%+12.72% 55.69B
Weighted average by Cap. -0.32%-1.02%+1.98%+15.15%

Financials

2025 2026 *
Net sales 104M 11.38M 9.65M 8.85M 8.4M 15.53M 1.06B 15.86M 40.82M 510M 42.67M 41.78M 1.8B -
Net income - -
Net Debt - -
Logo Senzime AB
Senzime AB (publ.) is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.
Employees
54
Date Price Change Volume
26-04-20 5.810 kr +5.64% 479,111
26-04-17 5.500 kr 0.00% 241,905
26-04-16 5.500 kr +6.59% 269,214
26-04-15 5.160 kr +7.61% 545,758
26-04-14 4.795 kr +4.92% 235,393

Quarterly revenue - Rate of surprise